ABBA CORD Trial: dCBT with Abatacept for Graft vs. Host Disease Prevention
Phase 2
20
about 3.7 years
18–65
1 site in OH
What this study is about
This trial is testing if adding abatacept to tacrolimus and mycophenolate mofetil (MMF) can prevent or reduce acute graft versus host disease (aGVHD) after a cord blood transplant in people with certain types of cancer. Participants will receive treatment, including a cord blood transplant and radiation therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Double Umbilical Cord Transplant
- 2.Receive Total Body Irradiation
- 3.Take Abatacept
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abatacept, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), tacrolimus, thiotepa
injection, intravenous, infusion, injection (Injection)
Secondary: Assessment of aGVHD biomarker REG3α, Assessment of aGVHD biomarker ST2, Disease free survival, Incidence of chronic GVHD, Non-relapse mortality, Overall Survival
radiation
Oncology